12391 related articles for article (PubMed ID: 11592301)
1. Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro.
Brooks TD; Slomp J; Quax PH; De Bart AC; Spencer MT; Verheijen JH; Charlton PA
Clin Exp Metastasis; 2000; 18(6):445-53. PubMed ID: 11592301
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
3. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Whitley BR; Palmieri D; Twerdi CD; Church FC
Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
[TBL] [Abstract][Full Text] [Related]
4. XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro.
Brooks TD; Wang SW; Brünner N; Charlton PA
Anticancer Drugs; 2004 Jan; 15(1):37-44. PubMed ID: 15090742
[TBL] [Abstract][Full Text] [Related]
5. Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
Praus M; Collen D; Gerard RD
Int J Cancer; 2002 Dec; 102(6):584-91. PubMed ID: 12447999
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells.
Liu G; Shuman MA; Cohen RL
Int J Cancer; 1995 Feb; 60(4):501-6. PubMed ID: 7829264
[TBL] [Abstract][Full Text] [Related]
7. uPA binding to PAI-1 induces corneal myofibroblast differentiation on vitronectin.
Wang L; Ly CM; Ko CY; Meyers EE; Lawrence DA; Bernstein AM
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4765-75. PubMed ID: 22700714
[TBL] [Abstract][Full Text] [Related]
8. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
9. The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
Tsuchiya H; Katsuo S; Matsuda E; Sunayama C; Tomita K; Ueda Y; Binder BR
Gen Diagn Pathol; 1995 May; 141(1):41-8. PubMed ID: 8542506
[TBL] [Abstract][Full Text] [Related]
10. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.
Khatib AM; Nip J; Fallavollita L; Lehmann M; Jensen G; Brodt P
Int J Cancer; 2001 Feb; 91(3):300-8. PubMed ID: 11169951
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
12. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Lobov S; Ranson M
Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
[TBL] [Abstract][Full Text] [Related]
13. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.
Takahashi T; Suzuki K; Ihara H; Mogami H; Kazui T; Urano T
Semin Thromb Hemost; 2005 Jun; 31(3):356-63. PubMed ID: 16052409
[TBL] [Abstract][Full Text] [Related]
17. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.
Chazaud B; Ricoux R; Christov C; Plonquet A; Gherardi RK; Barlovatz-Meimon G
Am J Pathol; 2002 Jan; 160(1):237-46. PubMed ID: 11786417
[TBL] [Abstract][Full Text] [Related]
18. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.
Waltz DA; Natkin LR; Fujita RM; Wei Y; Chapman HA
J Clin Invest; 1997 Jul; 100(1):58-67. PubMed ID: 9202057
[TBL] [Abstract][Full Text] [Related]
19. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
20. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
Bajou K; Masson V; Gerard RD; Schmitt PM; Albert V; Praus M; Lund LR; Frandsen TL; Brunner N; Dano K; Fusenig NE; Weidle U; Carmeliet G; Loskutoff D; Collen D; Carmeliet P; Foidart JM; Noël A
J Cell Biol; 2001 Feb; 152(4):777-84. PubMed ID: 11266468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]